Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 15

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 15
---
 service through the vesting date, with the exception of the RSUs granted to Dr. Lu in connection with her appointment to the Board, which vest in three equal installments on each anniversary of the date of grant , subject to continued service through each such vesting date. (3) Douglass Given retired from the Board effective as of December 31, 2024. (4) Dr. Lu joined the Board during fiscal year 2024 and her cash compensation was pro-rated for such fiscal year. (5) In connection with her appointment, Dr. Lu received a sign-on grant of restricted stock units valued at $761,666. As of the last day of fiscal year 2024, the directors held the following outstanding restricted stock unit (“ RSU ”) grants in the aggregate: Douglass Given — — 19,583; Michael S. Perry — 19,583; Mauro Ferrari —19,583; William Waddill — 19,583; Adeoye Olukotun — 19,583; Victoria Vakiener — 24,722; and Hongbo Lu — 24,080 RSUs. As of the last day of fiscal year 2024, the directors held the following outstanding option ("Options") grants in the aggregate: Douglass Given — 4,593; Michael S. Perry — 4,593; Mauro Ferrari —4,593; William Waddill — 4,593; Adeoye Olukotun — 4,593; Victoria Vakiener — 4,593 Options; and Hongbo Lu — 0.

| 18 |

2025 PROXY STATEMENT Director Compensation Vote Required; Recommendation of the Board The nominees listed above receiving more “FOR” votes than “AGAINST” votes, assuming a quorum is present, will be elected as directors to serve until their terms expire or until their successors have been duly elected and qualified. Because directors are elected by a majority of votes cast, abstentions from voting and broker non-votes, if any, will be excluded from the vote and will have no effect on its outcome.

| THE BOARD UNANIMOUSLY RECOMMENDS A VOTE                 
 “FOR”EACH OF THE NOMINEES FOR DIRECTOR IN PROPOSAL ONE. |

| 19 |

2025 PROXY STATEMENT Proposal Two — Advisory Vote to Approve Executive Compensation Proposal Two — Advisory Vote to Approve Executive Compensation The compensation paid to our Named Executive Officers (“ NEOs